Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year

Moderna (MRNA), once an unknown biotech firm, quickly rose to the top of the global vaccine market during the COVID-19 pandemic. Its mRNA technology platform created one of the world’s first and most widely used COVID-19 vaccines. 

Investors who recognized its potential early saw a dramatic increase in share price, with MRNA stock rising by 1,226.9% between 2020 and 2022.  

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.